Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. - Wikidata - awgldk - TriplyDB

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

http://www.wikidata.org/entity/Q45345804

about

Wnt signaling pathways in urological cancers: past decades and still growing Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor The TRC8 ubiquitin ligase is sterol regulated and interacts with lipid and protein biosynthetic pathways Interplay between scatter factor receptors and B plexins controls invasive growth Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function EGFR/Met association regulates EGFR TKI resistance in breast cancer Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells Metabolism of kidney cancer: from the lab to clinical practice Targeting the hepatocyte growth factor-cMET axis in cancer therapy The MET axis as a therapeutic target.State of the science: an update on renal cell carcinoma An overview of the c-MET signaling pathway Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis Unusual linkage patterns of ligands and their cognate receptors indicate a novel reason for non-random gene order in the human genome Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge Targeting RTK Signaling Pathways in Cancer Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance MET inhibitors in combination with other therapies in non-small cell lung cancer Met in urological cancers MET: a critical player in tumorigenesis and therapeutic target Targeted therapeutic strategies for the management of renal cell carcinoma The metabolic basis of kidney cancer Circulating biomarkers in advanced renal cell carcinoma: clinical applications Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma Mode of receptor binding and activation by plasminogen-related growth factors.Choosing the right cell line for renal cell cancer research

P2860

Q21245761-331CB405-1EEA-499F-80BF-6AD9038C83A3 Q24291722-50A6EBF6-785A-4013-BB41-5E51E4180E2F Q24294805-9D66EB3C-5770-4B80-9B3B-AF1BFDEADF91 Q24295561-2CBEA874-3366-48DE-8A70-3F3FAE819365 Q24307789-7FDA7A95-C502-495B-8212-0EA27A410500 Q24312781-1BD9CB28-03FF-4239-84F5-DA2A3F39641A Q24338635-DBE9532A-9508-49BB-B3F2-F54FDEAD7B84 Q24532663-ABD895D5-F16B-4451-BAB4-44E29A7B2BB6 Q24539769-AC5D41B2-C149-425E-B276-F9930BF8C2E3 Q24541450-580DC6BA-F5C7-41EF-BEC9-725ED3602CF9 Q24546366-ACB138F5-58E6-4D0D-8A8B-65AA72855E6B Q24554529-DEAEF072-F3E3-42BB-87E9-3B4D22366E5D Q24563513-7AE749FE-5A68-4B05-A8C0-B990E296E517 Q24600512-C5BED212-4122-4B20-9C69-12084AC23996 Q24606259-A2614E09-3171-42F9-B89B-5BBDCFFE942D Q24609682-7A31041D-E7B8-47C3-B9BA-9E2BE83499C1 Q24630685-9B823CFB-F47E-4794-B7F4-DEE5DF0A2261 Q24633986-F121A7CC-602B-4FD7-94DF-28FB8EB711E3 Q24645410-E6AA271C-DEA4-4BD2-BDA7-3F15BC463A7B Q24646295-7B593A82-239D-4618-B3A1-08C1F9EF651A Q24681561-5C3FBB1E-61F5-4BFB-8F45-A208695E9561 Q24683896-5719CC4A-54F5-44BE-9CA5-CE40C2B60F16 Q24815834-248F8C2B-2958-48B4-A644-79B98C3B613C Q26748581-BC7C7457-2730-42C5-A522-C58AC43BEECD Q26752381-F988DEF7-D7DA-4EB0-BD07-4428AA2B766E Q26781273-40E5F407-807D-49E2-A30C-635840FD23DF Q26781278-1FCD7EE5-BE05-4E4D-8B86-D83714BFDDC4 Q26799900-AFCD2E2A-DE7E-490B-913F-E4E35BFAFBB7 Q26823203-4E5FF09B-6020-48B6-821A-9E9BEEDE8615 Q26864988-82BAB21D-22B3-4D54-A282-F1D68665B584 Q27008925-E3AA700E-2741-4792-B9F2-DC649A9F3F37 Q27013846-2B5361DC-38C3-4D4C-A9B9-6921FD6BC7FE Q27023273-82D79595-4EC1-4367-8BA2-13AA0D9EF72B Q27023770-58A720F7-35D3-44CF-8645-A676136675B0 Q27308835-EFA191C9-AE63-47CD-B779-81651D835F4D Q27635335-3B5403DF-824B-4FC7-A70C-FEC92E53F53B Q27675641-DDFA0F96-D19F-4824-A9F4-EAA7AA57F413 Q27851979-9EB02348-5239-4974-B50A-5FD8D7866884 Q27867714-47AC2713-041F-4059-9000-61037A168D3E Q28073283-7E6029D1-13D6-4DFD-8514-46AC02FD55C1

P2860

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

http://www.wikidata.org/entity/Q45345804

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年学术文章

@wuu

1997年学术文章

@zh

1997年学术文章

@zh-cn

1997年学术文章

@zh-hans

1997年学术文章

@zh-my

1997年学术文章

@zh-sg

1997年學術文章

@yue

1997年學術文章

@zh-hant

name

Germline and somatic mutations ...... in papillary renal carcinomas.

@en

Germline and somatic mutations ...... in papillary renal carcinomas.

@nl

type

label

Germline and somatic mutations ...... in papillary renal carcinomas.

@en

Germline and somatic mutations ...... in papillary renal carcinomas.

@nl

prefLabel

Germline and somatic mutations ...... in papillary renal carcinomas.

@en

Germline and somatic mutations ...... in papillary renal carcinomas.

@nl

P1433

Q45345804-248B3575-6315-43E3-AFDD-5844ECC1ABEA

P1476

Q45345804-C95F12E3-04A4-413A-B979-F02633425F48

P2093

Q45345804-0279CAC1-B9E2-4E78-95F2-68DA7A3C7583

Q45345804-0E737D57-D74F-48F7-9293-4DB69C2FBF94

Q45345804-0F239C37-3846-4D40-8D35-EB3EBE075507

Q45345804-158CB96E-D1A1-4444-A2B1-694CA824B2C1

Q45345804-27856075-8288-4042-86C9-3E99CA1733A2

Q45345804-2D9A299B-0AA6-4A7E-A9E9-64F23662CDFE

Q45345804-2E41FAFF-9960-417F-AD37-F70E19908EAA

Q45345804-370BE2A3-B502-4306-95E0-7F55AEB4000B

Q45345804-3B2858F2-DCE6-4AF7-BF10-AF0072B5EC39

Q45345804-4211E90B-A24C-4658-8A26-0C02476E6516

P2888

Q45345804-015AB24C-0525-4501-B836-0BD2785C99AE

P304

Q45345804-D07AD0A0-1C65-44E4-A4EF-844354E57E22

P31

Q45345804-26C5D4A8-1E52-45E1-B3D2-A5B56D83E98B

P356

Q45345804-E948340C-6686-4780-86BA-5EB2EACE9741

P407

Q45345804-A0562D31-B15F-44F9-A7D2-B8F83331458D

P433

Q45345804-1935DDDB-4868-4C2B-B47C-53DAEC68488E

P478

Q45345804-633B7A29-305A-4C63-8200-99C5F778BDB7

P50

Q45345804-1D9AAA1F-83E9-4483-B1E9-194B78BC994C

P577

Q45345804-BF8E29DC-12F8-4789-9510-21C9C1548875

P5875

Q45345804-8BF4DF85-3643-4FDF-833B-09A8CD493AA2

P6179

Q45345804-397B2027-D29B-48DC-B47F-1A4560C4962A

P698

Q45345804-74305DD5-92AA-409A-9945-A835645AB1F3

P356

P1433

Nature Genetics

P1476

Germline and somatic mutations ...... in papillary renal carcinomas.

@en

P2093

Allikmets R

http://www.w3.org/2001/XMLSchema#string

Bergerheim UR

http://www.w3.org/2001/XMLSchema#string

Bernues M

http://www.w3.org/2001/XMLSchema#string

Brauch H

http://www.w3.org/2001/XMLSchema#string

Casadevall C

http://www.w3.org/2001/XMLSchema#string

Chen F

http://www.w3.org/2001/XMLSchema#string

Chidambaram A

http://www.w3.org/2001/XMLSchema#string

Choyke P

http://www.w3.org/2001/XMLSchema#string

Decker J

http://www.w3.org/2001/XMLSchema#string

Duh FM

http://www.w3.org/2001/XMLSchema#string

P2888

P304

68-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NG0597-68

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

1997-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14078828

http://www.w3.org/2001/XMLSchema#string

P6179

1035254306

http://www.w3.org/2001/XMLSchema#string

P698

9140397

http://www.w3.org/2001/XMLSchema#string